Which PK parameter is commonly used to adjust dosing in hepatic impairment, and what does it reflect?

Which PK parameter is commonly used to adjust dosing in hepatic impairment, and what does it reflect?

• A. Clearance (CLh or CLint); reflects reduced hepatic metabolism and clearance capacity.
• B. Volume of distribution; reflects tissue binding.
• C. Elimination half-life; reflects duration of effect.
• D. Renal clearance; reflects kidney function.

Answer: (D)

When dosing needs adjustment for hepatic impairment, the key parameter to look at is hepatic clearance (CLh) or intrinsic hepatic clearance (CLint). This reflects the liver’s ability to metabolize and clear the drug from the bloodstream. If the liver is impaired, enzymes and hepatocytes work less efficiently, so CLh drops. Lower clearance means the drug stays in the body longer, increasing overall exposure (higher AUC) and often lengthening the elimination half-life, which is why dose or dosing interval may need to be reduced. Understanding CLh involves both how much drug reaches the liver (hepatic blood flow) and how well the liver can metabolize it (intrinsic clearance). For drugs with low extraction, CLh is roughly fu × CLint, so reduced metabolic capacity directly lowers clearance. For high-extraction drugs, clearance depends more on blood flow but still falls with impaired intrinsic clearance. In any case, hepatic impairment tends to increase drug exposure, guiding the need to adjust the dose to avoid toxicity. Renal clearance, on the other hand, reflects kidney function and is the parameter typically used to adjust dosing in renal impairment, not hepatic.

When dosing needs adjustment for hepatic impairment, the key parameter to look at is hepatic clearance (CLh) or intrinsic hepatic clearance (CLint). This reflects the liver’s ability to metabolize and clear the drug from the bloodstream. If the liver is impaired, enzymes and hepatocytes work less efficiently, so CLh drops. Lower clearance means the drug stays in the body longer, increasing overall exposure (higher AUC) and often lengthening the elimination half-life, which is why dose or dosing interval may need to be reduced.

Understanding CLh involves both how much drug reaches the liver (hepatic blood flow) and how well the liver can metabolize it (intrinsic clearance). For drugs with low extraction, CLh is roughly fu × CLint, so reduced metabolic capacity directly lowers clearance. For high-extraction drugs, clearance depends more on blood flow but still falls with impaired intrinsic clearance. In any case, hepatic impairment tends to increase drug exposure, guiding the need to adjust the dose to avoid toxicity.

Renal clearance, on the other hand, reflects kidney function and is the parameter typically used to adjust dosing in renal impairment, not hepatic.